NTP 10th Report on Carcinogens. IARC Cancer Review: Group 2B IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 7 , 1987,p. 226.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human Inadequate Evidence IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 2 , 1973,p. 161.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Animal Sufficient Evidence IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 2 , 1973,p. 161.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) .

The Iron-dextran complex is a complex of ferric oxyhydroxide with dextrans of 5000 to 7000 daltons in a viscous solution containing 50 mg/ml of iron. With the CAS registry number 9004-66-4, it is also named as Ferric dextran. The classification codes are Drug / Therapeutic Agent; Hematinic; Hematinics; Hematologic Agents; Human Data; Reproductive Effect; Tumor data. It is dark reddish-brown liquid which is soluble in hot water, soluble in ethanol and other organic solvents. Additionally, Iron-dextran is combustible, unstable at a pH of 5 and decomposes at 149-158° F. It may be sensitive to prolonged exposure to air. The symptoms associated with exposure to Iron-dextran are headaches, vomiting, and dizziness. When not being used, product containers should be kept sealed and stored in a cool, dry place.

Uses of Iron-dextran complex: It is supplied as a parenteral preparation and is used as a hematinic. Furthermore, it used for the prevention and treatment of iron deficiency anemia of Pigs and other livestock, promoting growth and development.

When you are using this chemical, please be cautious about it as the following:
It may cause sensitization by inhalation and skin contact, so people should not breathe vapour. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. If you want to contact this product, you must wear suitable protective clothing, gloves and eye/face protection. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)

The following are the toxicity data which has been tested.

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
mouse	LD	intramuscular	> 450mg(Fe)/kg (450mg/kg)		British Journal of Pharmacology and Chemotherapy. Vol. 10, Pg. 375, 1955.
mouse	LD50	intravenous	460mg(Fe)/kg (460mg/kg)		Acta Poloniae Pharmaceutica. For English translation, see APPFAR. Vol. 18, Pg. 149, 1961.
mouse	LD50	oral	1gm(Fe)/kg (1000mg/kg)		British Journal of Pharmacology and Chemotherapy. Vol. 24, Pg. 352, 1965.
rabbit	LD	intramuscular	> 690mg(Fe)/kg (690mg/kg)		British Journal of Pharmacology and Chemotherapy. Vol. 10, Pg. 375, 1955.
rabbit	LDLo	intravenous	500mg(Fe)/kg (500mg/kg)		British Journal of Pharmacology and Chemotherapy. Vol. 10, Pg. 375, 1955.
rat	LD50	intraperitoneal	3gm(Fe)/kg (3000mg/kg)		Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971.
rat	LDLo	intramuscular	1617mg(Fe)/kg (1617mg/kg)		Acta Veterinaria Vol. 29, Pg. 21, 1979.